Bolt Biotherapeutics Announced That Updated Clinical Data From Its Phase 1/2 Dose-escalation Study Of BDC-1001 Will Be Presented In A Mini-oral Presentation At The European Society For Medical Oncology Congress 2023
Author: Benzinga Newsdesk | October 16, 2023 07:31am